A study to evaluate the efficacy and safety of apixaban for Venous Thromboembolism in patients with a BMI ≥ 40 mg/kg2 or weight ≥ 120 kg
Latest Information Update: 22 Dec 2021
At a glance
- Drugs Apixaban (Primary) ; Warfarin
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 22 Dec 2021 New trial record
- 13 Dec 2021 Primary endpoint (time to recurrence of VTE within 12 month) has been met, as per results published in the Pharmacotherapy
- 13 Dec 2021 Results published in the Pharmacotherapy